Targeting this gene could help prevent the spread of breast cancer, Yale study finds

NEW HAVEN — Triple-negative breast cancer is one of the most difficult breast cancers to treat, especially once it has spread to other parts of the body, but Yale Cancer Center researchers have maybe found a clue to keep it from metastasizing.

The CECR2 gene, which stands for cat eye syndrome chromosome candidate region 2, appears to allow breast cancer cells to migrate to other tissues. But if the gene is deleted, T cells in the body’s immune system can prevent the cancer from metastasizing, according to a statement.

“These study results are very encouraging because there are few effective treatments for triple-negative breast cancer once it has metastasized,” said study lead author Qin Yan, co-director of science at the Center. for Breast Cancer from the Yale Cancer Center. “We are constantly looking for new effective therapeutic strategies to help patients with this life-threatening disease.”

Research could mean better treatment for triple-negative breast cancer with immunotherapies. Targeted therapies for CECR2 have been developed by Genentech and the joint effort of Structural Genomics Consortium and Novartis, according to the article published Wednesday in the journal Science Translational Medicine.

“We will continue to investigate these important findings,” Yan said in the statement. “We are working to characterize the mechanisms by which CECR2 modulates gene expression and the tumor microenvironment using multiple state-of-the-art technologies. Additionally, we hope to develop small molecule CECR2 inhibitors for clinical studies.

Meiling Zhang, a research associate at the Yale School of Medicine, is the study’s lead author.

It was funded by the Department of Defense Breast Cancer Research Program, the National Institutes of Health, a Yale Cancer Center Class 61 Cancer Research Award, and the James Hudson Brown-Alexander Postdoctoral Fellowship. Brown Coxe.

Comments are closed.